Fox Run Management L.L.C. Acquires New Stake in Guardant Health, Inc. (NASDAQ:GH)

Fox Run Management L.L.C. bought a new position in Guardant Health, Inc. (NASDAQ:GH) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 12,084 shares of the company’s stock, valued at approximately $369,000.

Other institutional investors have also recently modified their holdings of the company. R Squared Ltd bought a new stake in shares of Guardant Health during the fourth quarter valued at approximately $26,000. SBI Securities Co. Ltd. bought a new stake in shares of Guardant Health in the 4th quarter worth $43,000. Kimelman & Baird LLC purchased a new position in shares of Guardant Health in the fourth quarter worth $58,000. Quantbot Technologies LP bought a new position in shares of Guardant Health during the fourth quarter valued at $80,000. Finally, Jones Financial Companies Lllp boosted its position in shares of Guardant Health by 43.5% during the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock valued at $82,000 after buying an additional 817 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Stock Performance

Shares of Guardant Health stock opened at $45.84 on Thursday. Guardant Health, Inc. has a fifty-two week low of $15.81 and a fifty-two week high of $50.89. The company has a market capitalization of $5.66 billion, a P/E ratio of -12.88 and a beta of 1.50. The company has a fifty day moving average of $44.37 and a 200 day moving average of $34.03.

Guardant Health (NASDAQ:GH) last released its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). The business had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. Analysts forecast that Guardant Health, Inc. will post -2.9 EPS for the current year.

Analysts Set New Price Targets

GH has been the subject of a number of recent analyst reports. Stephens reissued an “overweight” rating and issued a $55.00 target price on shares of Guardant Health in a research report on Wednesday. Piper Sandler increased their price objective on shares of Guardant Health from $34.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. JPMorgan Chase & Co. lifted their target price on shares of Guardant Health from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Scotiabank increased their price target on Guardant Health from $47.00 to $52.00 and gave the company a “sector outperform” rating in a report on Monday, February 24th. Finally, Canaccord Genuity Group lifted their price objective on Guardant Health from $42.00 to $60.00 and gave the stock a “buy” rating in a report on Monday, February 24th. Twenty investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $48.95.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.